SiBone (NASDAQ:SIBN) CEO Laura Francis Sells 1,901 Shares of Company Stock

SiBone (NASDAQ:SIBN – Get Free Report) CEO Laura Francis sold 1,901 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $23.18, for a total value of $44,065.18. Following the sale, the chief executive officer owned 351,275 shares of the company’s stock, valued at approximately $8,142,554.50. This trade represents a 0.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Laura Francis also recently made the following trade(s):

  • On Monday, November 16th, Laura Francis sold 14,953 shares of SiBone stock. The stock was sold at an average price of $23.33, for a total value of $348,853.49.
  • On Wednesday, November 4th, Laura Francis sold 75,000 shares of SiBone stock. The shares were sold at an average price of $25.30, for a total value of $1,897,500.00.
  • On Monday, October 12th, Laura Francis sold 38,006 shares of SiBone stock. The shares were sold at an average price of $20.05, for a total value of $762,020.30.
  • On Monday, August 24th, Laura Francis sold 25,972 shares of SiBone stock. The shares were sold at an average price of $20.12, for a total value of $522,556.64.
  • On Friday, August 21st, Laura Francis sold 3,923 shares of SiBone stock. The shares were sold at an average price of $20.02, for a total value of $78,538.46.
  • On Thursday, August 20th, Laura Francis sold 51,884 shares of SiBone stock. The stock was sold at an average price of $19.46, for a total transaction of $1,009,662.64.

SiBone Stock Up 1.6%

SIBN stock opened at $23.54 on Thursday. The company has a current ratio of 7.58, a quick ratio of 6.15 and a debt-to-equity ratio of 0.19. The firm has a 50 day simple moving average of $20.67 and a 200-day simple moving average of $16.89. The company has a market capitalization of $1.06 billion, a P/E ratio of -75.93 and a beta of 0.64. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.

SiBone (NASDAQ:SIBN – Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million for the quarter, compared to analysts’ expectations of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. On average, equities research analysts predict that SiBone will post -0.34 earnings per share for the current fiscal year.

Key Headlines Impacting SiBone

Investors following SIBN have been watching these headlines:

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SIBN. Goldman Sachs Group Inc. grew its position in shares of SiBone by 9.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 483,029 shares of the company’s stock valued at $9,081,000 after buying an additional 41,117 shares during the last quarter. Entropy Technologies LP acquired a new stake in SiBone during the third quarter worth about $768,000. Pathstone Holdings LLC bought a new position in SiBone in the third quarter worth about $346,000. Marshall Wace LLP lifted its holdings in SiBone by 1.2% in the third quarter. Marshall Wace LLP now owns 698,416 shares of the company’s stock worth $13,130,000 after acquiring an additional 8,128 shares during the last quarter. Finally, Royce & Associates LP lifted its holdings in SiBone by 15.7% in the third quarter. Royce & Associates LP now owns 457,088 shares of the company’s stock worth $8,593,000 after acquiring an additional 62,000 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SIBN has been the subject of several research analyst reports. Needham & Company LLC dropped their target price on shares of SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Tuesday, November 3rd. UBS Group increased their price target on shares of SiBone from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a research note on Wednesday. Citigroup reiterated a “market outperform” rating on shares of SiBone in a research note on Tuesday, November 3rd. Finally, Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

Get Our Latest Research Report on SIBN

About SiBone

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Featured Articles

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.